Research programme: ultra-long acting oral HIV therapies - Gilead Sciences/Lyndra
Latest Information Update: 21 Nov 2022
At a glance
- Originator Gilead Sciences; Lyndra
- Class Antiretrovirals; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical HIV infections
Most Recent Events
- 01 Nov 2022 Lyndra Therapeutics receives a notice of allowance from USPTO for its ultra-long-acting oral drug delivery system in USA
- 17 Oct 2022 Lyndra’s in-licenses patents that broadly covers the transformative LYNX™ drug delivery platform from Massachusetts Institute of Technology and Brigham & Women’s Hospital (Lyndra website, October 2022).
- 17 Oct 2022 Lyndra has patents pending for LYNX™ drug delivery platform worldwide (Lyndra website, October 2022)